XGENERA
LIVE

Serial Number

79433300

Owner

Xgenera Ltd

Attorney

William C. Wright

Filing Date

Jul 10, 2025

Add to watchlist:

No watchlists yet
View on USPTO

XGENERA Trademark

Serial Number: 79433300

XGENERA is a trademark filed by Xgenera Ltd on July 10, 2025. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 44 (Medical Services). The application is currently pending registration.

Owner Contact Info

Xgenera Ltd

313 Calmore Road,

Entity Type: 24

Trademark Details

Filing Date

July 10, 2025

Registration Date

Not Registered

Goods & Services

Diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, cancer and pre-cancerous conditions, cardiovascular and cerebrovascular diseases, neurological and neurodegenerative diseases, infectious diseases, inflammatory and autoimmune diseases, metabolic and endocrine diseases, respiratory disease, renal and urological diseases, reproductive related conditions; chemical preparations for testing blood for medical purposes; diagnostic preparations for medical purposes; diagnostic preparations for medical purposes used by medical laboratories; reagents for use in medical testing; diagnostic testing materials for medical use; medical diagnostic test strips for use in the field of oncology, cardiology, neurology, infectious disease, immunology, endocrinology, respiratory medicine, nephrology urology and obstetrics; medical diagnostic reagents; medical testing kits comprised of medical diagnostic reagents and assays for testing body fluids; diagnostic kits comprising diagnostic agents, preparations and substances for medical purposes; chemical preparations for the testing of blood and urine for medical purposes

Medical testing services; medical analysis services for the diagnosis and treatment of persons; medical testing services relating to the diagnosis and treatment of disease; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; medical testing and medical analysis services for diagnostic and treatment purposes provided by medical laboratories; medical screening; medical testing services for blood and urine testing; medical analysis services for diagnostic and treatment purposes provided by medical laboratories, namely, analysis of human blood, urine, tissue and cells for medical treatment and diagnostics; medical analysis services for the diagnosis of cancer; medical analysis services for diagnostic and treatment purposes provided by medical laboratories, namely, RNA or DNA analysis services for cancer diagnosis and prognosis; medical laboratory services for the analysis of samples taken from patients relating to the treatment of persons

Medical testing instruments and apparatus, namely, apparatus for medical diagnostic testing in the fields of cancer or other tissue-based diagnostic testing, cytology and cell-based testing; apparatus and instruments for use in medical analysis, namely, for detecting and measuring analytes in biofluids; testing probes and testing apparatus for medical diagnostic purposes, namely, medical diagnostic apparatus for testing cancer cells, human blood, urine, tissue, and biofluids; apparatus for DNA and RNA testing for medical purposes; diagnostic instruments for medical use, namely, medical diagnostic apparatus for testing biomarkers; medical test kits for identifying oncological, viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, hepatological, ophthalmic, respiratory, gastrointestinal, hormonal, dermatological, immune system related infection and disease; medical test kits for diagnostic cancer and pre-cancerous conditions, cardiovascular and cerebrovascular diseases, neurological and neurodegenerative diseases, infectious diseases, inflammatory and autoimmune diseases, metabolic and endocrine diseases, respiratory disease, renal and urological diseases, reproductive related conditions detection purposes; blood and urine testing and analysis apparatus and instruments

Filing History

TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 8, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 8, 2026 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 8, 2026 TROA
REFUSAL PROCESSED BY IB
Jan 29, 2026 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jan 15, 2026 RFCS
REFUSAL PROCESSED BY MPU
Jan 15, 2026 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Dec 6, 2025 RFCR
NON-FINAL ACTION WRITTEN
Dec 5, 2025 CNRT
ASSIGNED TO EXAMINER
Nov 28, 2025 DOCK
APPLICATION FILING RECEIPT MAILED
Sep 29, 2025 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 29, 2025 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Sep 25, 2025 REPR